Hallam Thomas
Known title: Chief Executive OfficerCIK: 0001850921
Hallam Thomas's purchase track record
How the stock did after each of Hallam Thomas's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since September 21, 2021
Stock higher 6 months later
0%
3 months: 0%
Median 6-month return
-77.4%
3 months: -58.6%
Beat the S&P 500
0%
median -70.0% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/16/2022 | PALI | $10K | -66.7% | -77.4% | -3.9% |
| 3/28/2022 | PALI | $12K | -58.6% | -90.1% | -20.1% |
| 9/21/2021 | PALI | $15K | -28.9% | -57.3% | +3.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| PALI | ▲ Buy | Open Market | 40,000 | $10K | 8/16/2022 | View on chart |
| PALI | ▲ Buy | Open Market | 10,000 | $12K | 3/28/2022 | View on chart |
| PALI | ▲ Buy | Open Market | 6,000 | $15K | 9/21/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Palisade Bio Gets FDA and Health Canada Clearances for PALI-2108
Palisade Bio received FDA clearance for an IND to test PALI-2108 in Crohn’s disease, with first enrollment expected in Q1 next year. The company also secured Health Canada clearance for its Phase 2b ulcerative colitis trial. These regulatory approvals expand the drug's development across inflammatory bowel disease, while the stock remains near its 52-week low.
Palisade Bio Gets FDA and Health Canada Clearances for PALI-2108. Palisade Bio received FDA clearance for an IND to test PALI-2108 in Crohn’s disease, with first enrollment expected in Q1 next year. The company also secured Health Canada clearance for its Phase 2b ulcerative colitis trial. These regulatory approvals expand the drug's development across inflammatory bowel disease, while the stock remains near its 52-week low.